<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01414452</url>
  </required_header>
  <id_info>
    <org_study_id>UAntwerpen</org_study_id>
    <nct_id>NCT01414452</nct_id>
  </id_info>
  <brief_title>Role of Adiponectin and Endothelial Progenitor Cells in Reperfusion Injury in Patients With Acute Myocardial Infarction</brief_title>
  <acronym>RÂ²ACE</acronym>
  <official_title>Reperfusion Injury and Cardiac Remodelling After Myocardial Infarction in Relation to Adiponectin Level, Circulating Endothelial Progenitor Cells and Endothelial Microparticles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universiteit Antwerpen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universiteit Antwerpen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is experimental evidence that low levels of adiponectin are associated with more
      reperfusion injury. In addition experimental studies have demonstrated that endothelial
      progenitor cells may have a favorable effect on remodeling, mainly through stimulation of
      neo-revascularisation. Clinical data on these issues are lacking. This clinical project
      studies the role of adiponectin, endothelial progenitor cells and endothelial microparticles
      in the ischaemia-reperfusion process and the compensatory ventricular remodelling in a
      population of 250 infarction patients treated with primary PCI. If the role of these factors
      could be confirmed in this clinical setting, those factors might represent a new target for
      therapeutic interventions in AMI patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>occurrence of reperfusion injury after succesfull primary PCI</measure>
    <time_frame>within 90 min after PCI</time_frame>
    <description>Serial ECG measurements (before and after PCI to assess extent of ST segment resolution as marker of reperfusion injury</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major cardiovascular event rate</measure>
    <time_frame>at 1 year</time_frame>
    <description>combined endpoint of hospitalisation (or extension of hospitalisation) for heart failure and cardiac death in a period of one year</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">250</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Reperfusion Injury</condition>
  <arm_group>
    <arm_group_label>STEMI patients</arm_group_label>
    <description>Patients with ST elevation myocardial infarction,lasting &lt;12 hour, who were succesfully treated with primary PCI</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        ST elevetion myocardial infarction patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  STEMI treated with primary PCI

        Exclusion Criteria:

          -  ischemia time &gt;12h

          -  use of immunosuppressive therapy

          -  unsuccessful recanalisation

          -  not-interpretable ST-T segment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Claeys, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Antwerp</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University hospital</name>
      <address>
        <city>Edegem</city>
        <state>Antwerp</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2011</study_first_submitted>
  <study_first_submitted_qc>August 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2011</study_first_posted>
  <last_update_submitted>July 19, 2015</last_update_submitted>
  <last_update_submitted_qc>July 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universiteit Antwerpen</investigator_affiliation>
    <investigator_full_name>M Claeys</investigator_full_name>
    <investigator_title>Prof dr</investigator_title>
  </responsible_party>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Reperfusion injury</keyword>
  <keyword>Adiponectin</keyword>
  <keyword>endothelial progenitor cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

